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Oligomannan Prebiotic Attenuates 
Immunological, Clinical and 
Behavioral Symptoms in Mouse 
Model of Inflammatory Bowel 
Disease
Szilamér Ferenczi1, Krisztián Szegi1, Zsuzsanna Winkler1, Teréz Barna2 & Krisztina J. Kovács1
Inflammatory bowel disease shows increasing prevalence, however its pathomechanism and 
treatment is not fully resolved. Prebiotics are non-digestible carbohydrates which might provide 
an alternative to treat inflammatory conditions in the gut due to their positive effects either on 
the microbiome or through their direct effect on macrophages and mucosa. To test the protective 
effects of an oligomannan prebiotic, yeast cell wall mannooligosaccharide (MOS) was administered 
in dextran-sulphate-sodium (DSS)-induced mouse model of acute colitis. MOS reduced DSS-induced 
clinical- (weight loss, diarrhea) and histological scores (mucosal damage) as well as sickness-related 
anxiety. DSS treatment resulted in changes in colon microbiome with selective increase of Coliform 
bacteria. MOS administration attenuated colitis-related increase of Coliforms, normalized colonic muc2 
expression and attenuated local expression of proinflammatory cytokines IL-1a, IL1b, IL6, KC, G-CSF 
and MCP1 as well as toll-like receptor TLR4 and NLRP3 inflammasome. Some of the protective effects 
of MOS were likely be mediated directly through local macrophages because MOS dose-dependently 
inhibited IL-1b and G-CSF induction following in vitro DSS challenge and IL1a, IL1b, G-SCF-, and 
IL6 increases after LPS treatment in mouse macrophage cell line RAW264.7. These results highlight 
oligomannan prebiotics as therapeutic functional food for testing in clinical trials.
Inflammatory bowel diseases (IBD, Crohn’s disease and ulcerative colitis) are characterized by recurrent inflam-
mation of the gastrointestinal tract affecting increasing number of patients worldwide.
Detailed pathomechanism of IBD is still unresolved, although combination of genetic, environmental and 
immunological factors has been implicated in the etiology of the disease1. Aberrant responses of the innate and 
adaptive immune system to commensal bacteria are widely implicated in IBD2. Classic conservative therapeutic 
strategies such as anti-inflammatory and/or immunosuppressive therapies, including use of steroids, antibiotics 
or tumor necrosis factor inhibitors have many serious side effects3,4 and there is an urgent need for alternative 
treatments.
Among the animals models of IBD developed so far, the dextran-sodium sulphate –induced colitis has high 
face validity to the pathogenesis of the human disease5. Susceptible strain of mice (C57Bl6) displays clinical and 
histological signs of gut inflammation which are similar to those seen in IBD patients.
In the normal gut, dendritic cells are continuously monitoring gut microbiota and help to develop tolerance 
to non-pathogenic bacteria. In IBD patients the epithelial barrier is compromised, allowing commensal bacte-
ria to infiltrate into the lamina propria that triggers local inflammation via release proinflammatory cytokines 
and propagation of inflammation via recruitment/proliferation of macrophages, neutrophils, and T and B cells. 
Clinical and experimental observations indicate an imbalance in protective and harmful bacteria in IBD patients. 
For instance, adherent and intramucosal bacteria are more abundant in patients with Crohn’s disease than in 
healthy controls6. Therefore, manipulation of the gut flora to enhance its protective and beneficial role represents 
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a new promising field to combat IBD. More recently, efforts to manipulate bacterial flora via probiotics or fecal 
transplants provide an alternative to treat IBD7. However, beneficial effects of these treatments in IBD were mod-
est, strain-specific and limited to certain manifestations of disease and duration of use of the probiotic8.
As an alternative, the use of prebiotics (non-digestible carbohydrates) is an emerging field to combat IBD. 
Until now, inulin and fructooligosaccharides (FOS) have been tested in IBD9. Based on recent glycomics 
advances, specific mannose-based oligosaccharides mannooligosaccharides (MOS) can be designed and tested in 
experimental IBD models for the following reasons: (1) pathogens with mannose specific fimbriae bind to MOS 
instead of colon epithelial cell surface thus preventing the damage of epithelial barrier and colonization of harm-
ful bacteria10; (2) MOS are selectively used by Bifidobacterium and Lactobacilli, thus boosting beneficial members 
of the gut flora11; (3) MOS might neutralize antibodies against mannose epitopes of the yeast Saccharomyces 
cerevisiae (ASCA)12 that have been characterized as serological marker in patients with Crohn’s disease; (4) MOS 
may act directly on macrophages to regulate cytokine production.
In this study we investigated the effects of a yeast cell wall mannooligosaccharide (MOS) on various markers 
of DSS-induced colitis in mice. In addition, the direct effect of MOS on murine macrophage cell line (RAW264.7) 
has also been evaluated.
Results
General physiology and sickness behavior. Control mice and MOS exposed animals did not display 
overt changes during treatment. Starting at day 3, DSS-treated mice showed sickness behavior with decreased 
locomotion and social withdrawal. At the end of the experiment, 71% of DSS-treated animals have anal prolapse 
and bloody feces, while only 25% of DSS + MOS treated animals had visible blood in the fecal sample.
Body weight change. There was significant effect of treatment on body weight gain (One way ANOVA, 
F(3, 18) = 6.69, p = 0.0035). Both DSS and DSS + MOS-treated animals lost significant weight during treatment, 
while body weight change of MOS-treated mice was not significantly different from that of the controls (Fig. 1a).
Food and fluid intake. One way ANOVA did not reveal significant difference between the groups in food 
consumption: F(3, 28) = 1.09, p = 0.37. No significant differences were found in fluid consumption between the 
groups (F3, 38) = 2.61, p = 0.06 (Fig. 1b).
Blood glucose. The blood glucose levels (Control: 9.22 ± 0.28; MOS: 9.42 ± 0.31; DSS:8.84 ± 0.36; 
DSS + MOS: 7.95 ± 0.49 mM) were not different when measured at the time of decapitation F(3, 19) = 2.54, 
p = 0.092.
Colon length and weight. One way ANOVA revealed significant treatment effect F(3, 18) = 54.36, 
p < 0.0001 on colon length. The colon was significantly shorter in DSS-treated mice than those of vehicle treated 
animals. MOS per os administration did not alter DSS effect on colon length. The colon weight/length ratio was 
significantly higher in DSS-treated animals when compared to control, MOS and DSS + MOS groups (ANOVA 
F(3, 18) = 7.04, p < 0.0035)(Fig. 1c).
Figure 1. MOS attenuates disease activity in mice during dextran sulphate sodium (DSS)- induced colitis. 
Mean ± SEM values for body weight gain during 8 days’ treatment (A) and daily food intake (B). At autopsy 
the colon weight/length ratio was calculated (C), mucosa thickness (D) was measured on histological sections. 
**p < 0.01 and *p < 0.05 compared to control mice; ++p < 0.01 and p < 0.05 compared to DSS-treated animals.
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Histopathology. No obvious histopathological abnormality was observed in control mice without chal-
lenge. DSS resulted in epithelial damage, decrease of mucosa thickness and crypt disintegration, signs of impaired 
mucus secretion and invasion of leukocytes into the lamina propria. Histological investigation of the colon in 
MOS treated animals revealed intact epithelium and increased number of goblet cells. In the DSS + MOS treated 
group significant goblet hyperplasia with relative intact epithelial layer was seen without leukocyte infiltration. 
Individual or summarized histopathological scores for inflammation, crypt damage and ulceration indicated less 
mucosal damage in DSS + MOS treated animals than that of DSS group. Representative examples of H&E stained 
material are shown on Fig. 2.
Mucosa thickness and muc2 expression. DSS treatment for 8 days significantly reduced the thickness of 
the colonic mucosa. MOS alone did not affect mucosal thickness, however, restored DSS-colitis induced reduc-
tion of the mucosal layer. (One way ANOVA F(3, 45) = 15.91; p < 0.0001) (Fig. 1d). Relative quantity of Muc2 
mRNA was decreased in DSS-treated mice (0.43 ± 0.03) which was normalized by MOS treatment (0.82 ± 0.11).
Composition of gut microbiome. Four main phyla of the mouse gut microbiome (Gram-negative 
Bacteroidetes and Proteobacteria and Gram-positive Actinobacteria and Firmicutes) have been analyzed from 
cecum and colon samples using qPCR analysis of phylum-specific 16S rRNA genes. Among these constitu-
ents, only Coliforms (Proteobacteria phylum) showed statistically significant change (ANOVA: F(3, 27) = 7.03; 
p = 0.0015) with an increase in DSS-treated mice (p < 0.01), which was attenuated by MOS treatment (p < 0.01 
DSS vs. DSS + MOS). MOS treatment alone had no effect on the quantity of genomic DNA corresponding to 
Coliform’s 16S rRNA when compared to controls (Fig. 3.)
Behavior in Open Field Test. We compared the behavior of mice in open field test, an anxiety-related 
behavioral paradigm (Fig. 4). There was significant effect of treatment on time spent in the center (One way 
ANOVA, F(3, 16) = 5.441, p = 0.009). MOS-treated mice spent significantly more time in the centrum of open 
field apparatus than DSS-treated animals. DSS treatment significantly decreased locomotor activity (One way 
ANOVA, F(3, 16) = 3.637, p = 0.0357). DSS also decreased exploration (One way ANOVA, F(3, 16) = 3.416, 
Figure 2. Representative photomicrographs taken from hematoxylin-eosin stained colon sections of 
control, MOS treated, DSS-treated and DSS + MOS-treated mice. Note the epithelial erosion, disintegrated 
crypts and piling of leukocytes in DSS-treated animals.
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p = 0.0430). In this test there was no difference in horizontal and vertical movement between MOS-treated ani-
mals and control mice.
Cytokine/chemokine mRNA expression in the colon. Because significant piling of leukocytes was seen 
on histological preparations of DSS-treated animals, which was prevented by MOS, next, we measured mRNA 
expression of select chemokines and cytokines that are implicated in leukocyte trafficking, recruitment and acti-
vation (Fig. 5).
Cytokine/chemokine mRNA expression in the colon during DSS-induced colitis. DSS-colitis increased mRNA 
expression of interleukin IL-1a , IL-1b , IL-6, tumor necrosis factor TNFa, keratinocyte chemoattractant KC/
CXCL1, granulocyte colony-stimulating factor, G-CSF and MCP-1. In contrast, no significant changes were found 
in the expression of IL-10, IL-17, arginase and fractalkine (CX3CL1) in colon samples of DSS-treated mice.
Effect of MOS on cytokine/chemokine expression in control mice. Per os treatment of control mice with mannool-
igosaccharide (MOS) increased the expression of fractalkine and decreased mRNA levels of arginase and KC. The 
expression of cytokines in the gut remain unchanged.
Effect of MOS on DSS-colitis induced cytokine/chemokine expression. MOS treatment significantly reduced 
DSS-colitis induced IL-1a, IL-1b, IL-6 (F(3,11) = 6.99 p = 0.012), G-CSF, KC and MCP-1 expression. In case of 
TNFa, however, MOS was ineffective in reducing DSS-induced cytokine mRNA levels.
Figure 3. Changes in Coliform bacteria in the colon. Data are expressed as log10 copy number/ng genomic 
DNA isolated from colon content of control, MOS-treated, DSS-treated and DSS + MOS-treated animals. 
***p < 0.001 compared to control.
Figure 4. MOS affects mouse anxiety behavior. Effects of MOS and DSS on the locomotor activity, exploratory 
behavior and time spent in the centrum of open field test. Mean ± SEM values. Mice with DSS-induced colitis 
display decreased locomotion and exploration, corresponding to sickness behavior. MOS-treated mice are less 
anxious than control as they spend more time in the open field centrum. *p < 0.05 vs control.
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Receptors and signal transduction. Toll like receptors. MOS treatment significantly reduced expression 
of TLRs 2, 4 and 7, while did not affect TLR9. DSS-treatment for 8 days resulted in elevated mRNA levels of TLR4 
and TLR7, while expression of TLR2 and TLR9 did not change in colitis mice (Fig. 6).
Nucleotide-binding oligomerization-domain protein-like receptors (NLRs). NALP3. One way ANOVA revealed 
significant effect on NALP3 expression: F(3, 11) = 11.34, p = 0.003. Relative expression level of NALP3 was signif-
icantly higher in DSS-treated animals compared to controls. RQs were 2.77 ± 0.18 in DSS treated- vs. 1.11 ± 0.11 
in vehicle treated controls. Relative quantities values for NALP3 were not different in MOS treated animals when 
compared to controls. MOS application decreased DSS-induced NALP3 expression to a level, which is not sig-
nificantly different from control (RQ = 1.10 ± 0.08 in DSS + MOS vs. 1.11 ± 0.11 in vehicle treated controls, 
p > 0.05).
Figure 5. MOS prevents DSS-induced upregulation of select proinflammatory cytokines and chemokines 
in the colon. Mean ± SEM values of relative mRNA quantities in the colon of mice that were treated with 
MOS, DSS or DSS + MOS. Cytokine mRNA levels were normalized to GAPDH levels and expressed as relative 
quantity (RQ) compared to the value of untreated control set to 1. *p < 0.05, **p < 0.01, ***p < 0.001 compared 
to control mice; +p < 0.05, +++p < 0.001 compared to DSS treated animals.
Figure 6. Dextran sulphate sodium and MOS exposure affects Toll-like and NOD-like receptors in the 
mouse colon. Mean ± SEM values of relative mRNA quantities in the colon samples of mice that were treated 
with MOS, DSS or DSS + MOS. Receptor mRNA levels were normalized to GAPDH levels and expressed 
as relative quantity compared to the value of untreated control set to 1. *p < 0.05, **p < 0.01, ***p < 0.001 
compared to control mice; +p < 0.05 compared to DSS treated animals.
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NALP6. 8 days treatment with MOS significantly reduced NALP6 mRNA levels in the colon of vehicle-treated 
control mice F(3, 17) = 27.68, p < 0.001. DSS alone or in combination with MOS did not alter relative quantities 
of this receptor.
Plasma cytokine levels. Among the 11 cytokines investigated, cytometric bead array (CBA) did not reveal 
detectable levels of IL-1a, IL-1b, IL-17a and IL-10 in the control mouse plasma. As analyzed by t-tests, circulating 
levels of KC (p = 0.0035, t = 3.377 df = 10), G-CSF (p = 0.039, t = 1.961 df = 10) and IL-6 (p = 0.0002, t = 5.211 
df = 10) were significantly elevated in mice with DSS-colitis. Plasma levels of most cytokines did not change in 
control animals treated with MOS, however increased concentration of G-CSF was detected after oligosaccharide 
administration (p = 0.014, t = 2.875 df = 6) (Fig. 7).
MOS treatment successfully prevented DSS-induced KC levels (One way ANOVA: F(3, 18) = 7.87, p = 0.002). 
In case of G-CSF there was a tendency for reduction by oligosaccharide, however, the difference between DSS 
and DSS + MOS groups did not reach significance due to high individual variation. Elevated plasma levels of IL-6 
seen in DSS colitis group was not reduced by MOS.
In vitro effects of MOS on RAW 264.7 macrophage cells. To assess the direct effect of MOS on mac-
rophages, a murine macrophage cell line, RAW 264.7 was treated with MOS alone and in combination with DSS 
or LPS. MOS alone does not induce expression of IL-1a, IL-1b, TNFa or KC, however, 100 μ g/ml dose significantly 
elevated the mRNA level of G-CSF. By contrast the RQ levels of IL-6 mRNA were reduced in all MOS treated cells, 
however the decrease was not significant. LPS as an inflammatory challenge, resulted in significant elevation of 
all cytokine expression except KC. LPS-induced proinflammatory cytokine mRNA levels were significantly and 
dose-dependently reduced by MOS except TNFa. DSS treatment selectively increased the expression of IL1b and 
G-CSF and this elevation was completely prevented by MOS administration (Fig. 8).
Discussion
Here we have provided evidence that yeast mannooligosaccharide (MOS) with beta 1,4 linkage is effective to 
relive symptoms of inflammatory bowel disease by reducing colitis-related increase of Coliform bacteria, expres-
sion proinflammatory mediators and boosting mucus production in the sodium dextran sulphate-induced colitis 
model in mice.
Methodical considerations. Sodium dextran sulphate (DSS)-induced colitis is extensively used to model 
inflammatory bowel disease and screen therapeutic interventions in rodents13,14. Our experiments were per-
formed in C57Bl6 mouse strain, which is more susceptible to DSS than other strains such as CD1 or BalbC15,16. 
Colitis was induced by addition of DSS to drinking water. As the fluid intake was not different among the different 
treatment groups, the beneficial effect of MOS may not due to differences in DSS-water consumption. Our exper-
imental design (8 day oral DSS exposure) corresponds to an active colitis and recapitulates many clinical features 
of human ulcerative colitis (UC)14.
DSS-induced colon inflammation. We have confirmed significant pathological- (body weight loss, diar-
rhea, reduced colon length), and histological- (reduced mucosa thickness and epithelial damage) alterations in 
DSS- treated mice17,18. Although the mechanism with which DSS induces colonic inflammation in mice is not 
fully clear, it is generally held that DSS is toxic to gut epithelia, induces erosions and compromises gut barrier19. 
Impaired barrier functions (leaky gut) allow the invasion of luminal bacteria and induce local innate immune 
response at the gut associated lymphoid tissue.
IBD is manifest in the context of commensal microbes. Studies of experimental animal models of IBD reveal 
that germ-free mice normally display only a few signs of inflammation and for the full effects of experimental 
colitis exposure to natural microbial communities is necessary. Although there is still a considerable controversy 
whether the entire commensal microbiota or individual pathogens (e.g. Mycobacterium avium spp. paratuber-
culosis) are primarily responsible for induction of inflammation. Colonic disbiosis have been implicated in the 
pathogenesis of human IBDs20, with a decrease of relative abundance of Enterobacteria and Firmicutes and an 
Figure 7. DSS treatment elevates plasma levels of KC, G-CSF and IL-6. Mean ± SEM values of KC, G-CSF 
and IL-6 in plasma samples of mice that were control or exposed to DSS and treated with vehicle or MOS. 
*p < 0.05, **p < 0.01 compared to control mice; +p < 0.05 compared to DSS treated animals.
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increase of Proteobacteria and Actinobacteria in case of UC21. Furthermore, the numbers of Enterobacteriaceae 
in colonic biopsies of IBD patients were 3–4 logs higher than in the controls22. Here we also show a selective 
increase of Coliform bacteria in the colon and cecum content of DSS-treated mice, which confirms similari-
ties between DSS mouse model and human UC. These Gram negative bacteria, which are recognized as path-
ogen signals by toll-like receptor-expressing cells of the innate immunity to induce inflammation via release 
of various proinflammatory mediators23,24. Furthermore, colonic inflammation is accompanied by significant 
recruitment of leukocytes to the submucosa. Along these lines, elevated expression of various chemo-attractants, 
such as monocyte chemotactic protein 1 (MCP-1, CCL-2), keratinocyte chemoattractant (KC or CXCL1) and 
fractalkine (CX3CL1) has been detected in the colon of DSS-treated animals corresponding to recruitment of 
neutrophils, monocytes and macrophages, respectively25–27. It has been recently shown that DSS is associated 
with medium-chain-length fatty acids (MCFAs) to form nanometer sized particles, which may act as intracellular 
danger associated molecular patterns (DAMPs) in the colonic mucosa together with luminal bacteria (PAMPs) 
to trigger inflammatory pathways28. Indeed, we have detected significant upregulation of toll like receptors (TLR 
4, TLR 7 and TLR 9) as well as NOD-like receptors whose activation ultimately results in synthesis and release of 
proinflammatory cytokines, IL-1a, IL-1b, IL-6 and TNFa in the colon of DSS-treated mice. The inflammasome 
NLRP3 plays a crucial role in the pathogenesis of colitis as shown recently in NLRP− /− mice18. Our present 
results confirm these findings by revealing elevated NALP3 mRNA levels in the inflamed colon. By contrast, 
according to Zaki et al. NLRP3 inflammasome protects against epithelial injury in DSS colitis29.
Protective effects of MOS in DSS-induced colitis. When MOS was given to DSS-treated mice it pre-
vented and/or significantly attenuated colitis symptoms although MOS administration in control animals did not 
result in overt changes in physiological parameters or clinical scores. The beneficial effects of various prebiotics, 
such as oligofructose and inulin on gastrointestinal and immune homeostasis have already been suggested9,30–33, 
however, the effects of mannooligosaccharides have not been fully addressed. From our present data it is very 
likely that MOS targets different loci in colitis pathomechanism. For instance, MOS is able to capture pathogenic 
bacteria through direct interaction with specific receptors, has a protective effect through stimulation of mucus 
production34 and it is very likely that MOS has a direct effect on gut associated lymphoid tissue (GALT) i.e. on 
macrophages35.
Figure 8. MOS prevents LPS or DSS-induced cytokines in RAW 264.7 mouse macrophage cell line. 
Mean ± SEM values of relative mRNA quantities measured in RAW 264.7 macrophages following DSS (5 μ g/ml) 
or LPS (100 ng/ml) and 0, 10, 100, 500 μ g/ml MOS administration. **p < 0.01, ***p < 0.001, ****p < 0.0001.
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There is compelling evidence for binding of MOS to FimH, a mannose specific lectin expressed in Gram 
negative bacteria with Type1 fimbriae, such as Salmonella36 or pathogenic E. coli37,38. This competitive inter-
action significantly reduce bacterial adherence to intestinal epithelial cells bearing mannose-containing gly-
coprotein receptors. Our present data revealed that MOS attenuated the increase of Coliform bacteria in the 
DSS- treated mouse colon. Furthermore, the presence of MOS likely serves to opsonize the bacteria by attracting 
mannan-binding lectin (MBL), a normal acute phase protein considered a part of the lectin pathway of the innate 
immune system, leading to opsonophagocytosis of the bacteria.
Previous research revealed interactions of different oligosaccharides (MOS, FOS and inulin) with carbohy-
drate receptors (mannose receptors, galectin family receptors, and Toll-like receptors) located on either epithelial 
or immune cells in the gastrointestinal tract30,39. For instance, a double-blind placebo controlled human study on 
ulcerative colitis patients revealed significant immunomodulatory effect of a symbiotic containing FOS and inulin 
with reduced levels of beta defensins, IL-1 and TNFa mRNA and improvement of the full clinical appearance of 
chronic inflammation40. Our results on RAW264.7 cells suggest that MOS has a direct effect on macrophages by 
preventing LPS or DSS-induced IL-1b and GCSF mRNA.
One intriguing finding of the present study is that DSS treatment and MOS administration affected the behav-
ior of the animals. MOS in control animals resulted in decreased anxiety and increased exploration. By con-
trast, DSS-treated animals showed sickness behavior with significant reduction of locomotor activity and signs of 
increased anxiety (more time spent in the periphery of the open field), which was not affected by MOS adminis-
tration. Indeed, it has been shown that anxiety and depression are common psychiatric symptoms in patients with 
chronic gut disorders, including those with overt inflammatory conditions of the gastrointestinal tract, such as 
inflammatory bowel disease. Although the mechanisms of gut-brain interactions are not fully described, inflam-
matory mediators (i.e. IL-1), which are released in the gut are able to affect directly or indirectly the central 
nervous system functions41.
Taken together, our results highlight protective effect of yeast cell wall mannooligosaccharide (MOS) on 
clinical-, histological and behavioral symptoms in the mouse model of inflammatory bowel disease. MOS acts 
directly on macrophages to relive production of proinflammatory mediators and indirectly by attenuating bac-
terial burden and via increased mucin expression. These findings identify MOS as a potential functional food 
ingredient for human clinical trials.
Materials and Methods
Animals. Adult (8–10 weeks old) male C57Bl6/J mice were obtained from the local colony bred at the Medical 
Gene Technology Unit (Specific Pathogen Free, SPF level) at the Institute of Experimental Medicine Budapest 
Hungary. Animals were housed at the Minimal Disease (MD) level, 3–5/cage under controlled environmen-
tal conditions: temperature, 21 °C ± 1 °C; humidity, 65%; light-dark cycle, 12-h light/12-h dark cycle, lights on 
at 07:00. Mice had free access to rodent food and water. All procedures were conducted in accordance with 
the guidelines set by the European Communities Council (86/609/EEC/2 and 2010/63 Directives of European 
Community) and the protocol was approved by the Institutional Animal Care and Use Committee of the Institute 
of Experimental Medicine, Budapest Hungary (permit numbers: 22.1/3347/003/2007 and PEI/001/29-4/2013).
Materials. Dextran sulphate sodium (DSS) was purchased form (MP Biomedicals, Santa Ana, CA, USA; cat 
#160110, Mw: 36000–50000). MOS was obtained from Alltech (Kentucky, USA).
Experimental Procedure. Animals were handled for 3–5 days to get acquainted with oral gavage using 
water only. Four experimental groups were then formed: (1) control, (2) yeast cell wall mannooligosaccharide 
(MOS) treated; (3) dextran sulphate (DSS)-treated and (4) DSS + MOS treated animals. Mice in groups 1 and 2 
received tap water to drink while animals in groups 3 and 4 had 3.5% (w/v) DSS to drink. MOS or vehicle (water) 
was given through oral gavage. Both DSS and MOS treatments started at the same time and lasted for 8 days. 
Mannooligosaccharide was dissolved in drinking water and applied at the dose of 500 mg/kg bw) which was 
selected on the basis of our pilot dose-response study (100–500–1000 mg/kg/day) where the clinical scores were 
evaluated only.
Body weight of the animals has been measured every day during treatment. Physiological status, general 
behavior of the animals and stool consistency were also recorded on a daily basis.
Behavior analysis. On the last treatment day (before dosing MOS/vehicle), behavior of the animals was 
tested in open field (white plastic box 40 × 40 × 30 cm). Mice were placed in the center of the box and allowed to 
explore the apparatus for 5 min. Behavior was recorded by video camera and analyzed by H77 computer based 
event recorder-program (Jozsef Haller, Institute of Experimental Medicine, Budapest, Hungary). Locomotor 
activity was calculated from total horizontal and vertical movement. Central area exploration was also recorded 
to provide an additional measure for anxiety.
At the end of the treatments, mice were quickly decapitated trunk blood collected in ice cold EDTA contain-
ing plastic tubes, centrifuged and the plasma stored at − 20 °C until assay. After decapitation, a drop of blood was 
applied to the D-Cont Personal blood glucose meter (77 Elektronika LTD Budapest, Hungary) for blood glucose 
measurement.
Cecum and colon was exposed by midline laparotomy, the length and weight of the colon (after feces removal 
by flushing with PBS) was measured and processed for biochemical and histological evaluation.
Histology. Tissue samples were fixed in 10% formalin and embedded in paraffin. 5 μ m sections were cut, 
stained with hematoxylin-eosin, scanned by tissue scanner (3D Histech Budapest, Hungary) and evaluated by 
Pannoramic Viewer 1.15 program (3D Histech, Budapest, Hungary).
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Cell culture. Murine macrophage cell line, RAW 264.7 was purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA) and cultured in DMEM supplemented with 10% heat inactivated fetal 
calf serum and antibiotics (100 units/mL of penicillin and 100 μ g/mL of streptomycin). 5 × 104 cell were plated 
onto 24 well plastic culture dishes and treated with MOS (10, 100 and 500 μ g/ml) for 2 hours and then challenged 
either with DSS (5 μ g/ml) or LPS (100 ng/ml) for 24 h. Supernatants were collected, cells washed and 500 μ l TriSol 
reagent was added to each well.
Real time qPCR measurements. For quantitative real time PCR measurements, tissue samples were cut 
and immediately frozen in dry ice. Total RNA was isolated from colonic and cell culture samples with QIAGEN 
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according the manufacturer’s instruction. To eliminate genomic 
DNA contamination DNase I treatment was used (100 μ l RNase-free DNase I (1 U DNase I, Fermentas) solu-
tion was added). Sample quality control and the quantitative analysis were carried out by NanoDrop (Thermo 
Scientific). Amplification was not detected in the reverse transcription (RT)-minus controls. cDNA synthesis 
was performed with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, 
USA). The designed primers (Invitrogen) were used in the Real-Time PCR reaction with Power SYBR Green PCR 
master mix (Applied Biosystems, Foster City, CA, USA) on ABI StepOnePlus instrument. The gene expression 
was analyzed by ABI StepOne 2.3 program. The amplicon was tested by Melt Curve Analysis on ABI StepOnePlus 
instrument. GAPDH was used as endogenous control reference gene and all data were normalized to GAPDH 
expression. Primers used for the comparative CT experiments were designed by the Primer Express 3.0 program 
(Applied Biosystems). Primer sequences are given in the supplementary material.
Analysis of gut microbiome. Phylum-specific primer sets targeting bacterial 16S rRNA genes were used 
to quantitate intestinal bacteria by using DNA extracted from feces and real-time PCR42. 100 and 200 mg fecal 
content from the colon and cecum, respectively, was collected at the autopsy and frozen on dry ice. Bacterial 
DNA content was isolated with QIAamp DNA Stool Mini Kit (Qiagen) according the manufacturer’s instruction. 
Sample quality control and the quantitative analysis were carried out by NanoDrop (Thermo Scientific, USA). 
Quantification was done by using standard curves made from known concentrations of the respective amplicon 
for each set of primers. The Real-Time PCR reactions with Fast EvaGreen qPCR Master Mix (Biotium, USA) were 
carried out on ABI StepOnePlus instrument. The results were analyzed by ABI Step One 2.3 software. The ampli-
cons were tested by Melt Curve Analysis on ABI Step OnePlus instrument. Copy number (CN) was calculated 
with the following formula: CN = A*6 × 1023/(L*660)*1 × 109 ng/g; where A is the amount of the amplicon in ng, 
L is the length of the amplicon and 660 is the average MW of 1 bp double stranded DNA.
Plasma cytokine measurement. Plasma samples were processed for cytokine measurement using 
Cytometric Bead Array (CBA Flex Sets BD Biosciences, UK). Eleven key cytokines/chemokines were assessed: 
IL-1α , IL-1β , G-CSF, IFNγ , IL-6, IL-10, IL-17A, KC, MCP-1, TNFα and RANTES (CCL5). The detection limit 
for each cytokine was 5–10 pg/ml.
Statistics. Data are mean ± SEM. Statistical tests were done on GraphPad Prism 6.0 program. Multiple 
groups were compared by one way analysis of variance (ANOVA) and post-hoc tests between individual groups. 
Body weight changes were analyzed by repeated measures of ANOVA. Level of significance was set as p < 0.05.
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